Intervention

Sacituzumab tirumotecan

ClinicalTrials.gov intervention label

Clinical trials18
Recruiting8
Common conditions24
Lead sponsors shown6

Clinical trials

18 shown
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)NCT07286149 · 2026-04-30
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14
RECRUITING
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · 2024-04-03
RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788 · 2023-12-15
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16
RECRUITING
Sac-TMT for Active TNBC Brain MetastasesNCT07458113 · 2026-08-01
NOT_YET_RECRUITING
Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung CancerNCT07702305 · 2026-06-23
NOT_YET_RECRUITING
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBCNCT07244874 · 2025-12-01
NOT_YET_RECRUITING
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerNCT07109284 · 2025-09-01
NOT_YET_RECRUITING
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLCNCT07703228 · 2025-08-13
ACTIVE_NOT_RECRUITING
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)NCT06788912 · 2025-03-20
ACTIVE_NOT_RECRUITING
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)NCT06483334 · 2024-07-17
ACTIVE_NOT_RECRUITING
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)NCT06305754 · 2024-06-11
ACTIVE_NOT_RECRUITING
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)NCT06074588 · 2023-11-12
ACTIVE_NOT_RECRUITING
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)NCT06049212 · 2023-10-26
ACTIVE_NOT_RECRUITING

Common conditions

Non-small Cell Lung Cancer (NSCLC)3Breast Neoplasms2Lung Neoplasm Malignant2Triple Negative Breast Neoplasms2EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis1ER+HER2- Breast Cancer1Esophageal Squamous Cell Carcinoma1HR Low-Positive/HER2-Negative Breast Neoplasms1Locally Advanced Urothelial Carcinoma1Metastases1Metastatic Triple Negative Breast Cancers1Metastatic Urothelial Carcinoma1Non Small Cell Lung Cancer1Non-small Cell Lung Cancer1NSCLC (Advanced Non-small Cell Lung Cancer)1NSCLC Stage IIIB~IV1PD-L1 Positive1Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)1Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)1Programmed Cell Death-1 (PD1, PD-1)1Second-line Therapy1Solid Tumors1TNBC - Triple-Negative Breast Cancer1Triple-Negative Breast Cancer1

Trial status mix

RECRUITING8
ACTIVE_NOT_RECRUITING6
NOT_YET_RECRUITING4

Phase mix

PHASE28
PHASE38
PHASE15

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.